We're trimming a health-care stock on concerns its business could be hurt by Eli Lilly

  • 📰 CNBC
  • ⏱ Reading Time:
  • 20 sec. here
  • 10 min. at publisher
  • 📊 Quality Score:
  • News: 39%
  • Publisher: 72%

Breaking News: Markets News

Markets,Investment Strategy,Jim Cramer

The sale will decrease its weighting in the portfolio to 2.34% from 2.66%.

We are selling 100 shares of Abbott Laboratories at roughly $110.84. Following the trade, Jim Cramer's Charitable Trust will own 700 shares of ABT, decreasing its weighting in the portfolio to 2.34% from 2.66%. We're trimming our Abbott Laboratories exposure on concerns that Wall Street will temporarily turn on diabetes device makers in reaction to Club holding Eli Lilly 's impressive new study for GLP-1 obesity drug Zepbound.

But it could take some time. Additionally, in similar thinking to our sale two weeks ago , shares of Abbott have curiously rallied more than 5% since an adverse verdict in late July in its first premature infant formula case in Missouri. We still think Abbott has lost more in market capitalization since this legal risk emerged in March than what a potential settlement could look like.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in CA
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Canada Canada Latest News, Canada Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

10 things to watch in the stock market Friday including more bullishness on Eli LillyWall Street is lower Friday morning after a strong session Thursday extended the market comeback.
Source: CNBC - 🏆 12. / 72 Read more »